author-photo

Filippo de Braud

University of Milan
European Institute of Oncology

646

Papers

16430

Citations

Citation Trend

Filter By

Papers (439) Sort By

Journal Conference Others

Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors

2021 Journal of Personalized Medicine
Show All
- Source
- Cite
- Save
Citations (0)
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (8)
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology

2021 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab{plus minus}Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (6)
The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-trastuzumab-pertuzumab

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (4)
A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Risk assessment of thromboembolic events in hospitalized cancer patients.

2021 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (0)
Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)